Pfizer Bets $15 Billion on New Class of Generic Drugs. Biotechnology and Bioengineering, Drugs (Pharmaceuticals), Generic Brands and Products, Mergers, Acquisitions and Divestitures, Hospira Inc, Pfizer Inc